The company had slightly more than $1 million in total revenues, down from $2.1 million during the same quarter in 2003. Product revenues were $410,000 for the fourth quarter of 2004, compared to $1.1 million for the prior-year period.
R&D costs for Q4 2004 were $5.2 million, a $700,000 increase in spending from $4.5 million during the same period a year ago.
Nanogen's net loss for the quarter amounted to $11.2 million, or $.31 per share, compared to a net loss of $5.9 million, or $.25 per share, during the fourth quarter of 2003.
As of Dec. 31, Nanogen had a cash position of $51.9 million. Of that, $15.4 million is in the form of cash and cash equivalents, with the remainder in the form of short-term investments.
The firm's cash holdings benefitted from a $5.7 million cash infusion after it acquired Epoch Biosciences for $97 million in December 2004.
Howard Birndoff, Nanogen's CEO and chairman of the board, said in a statement that his company plans to increase revenues in 2005 by launching three new products that will be based on the product portfolios the company gained following the merger with Epoch, and an April 2004 merger with SynX.
Birndoff said he expected total revenue for 2005 would increase three-fold as compared to 2004.